Table 2.

Characteristics of included studies about interleukin changes during treatments.

Study ID	Region	PMID	No.	Researched protein	Period	NOS
							Bilal N., 2021	Turkey	32776303	10	IL-6, IL-8	3M	6
Salman M.A., 2020	Egypt	–	79	IL-6	12M	6
Huang Y.S., 2020	China	32260590	55	IL-1β, IL-6, IL-10	6M	8
Chuang H.H., 2020	China	32093397	60	IL-1β, IL-8, IL-10	3M	8
Wang X., 2020	China	32799042	54	IL-6	3M	8
Borges Y.G., 2020	Brazil	31313021	18	IL-6, IL-10	2M	8
Recoquillon S., 2019	France	30366971	55	IL-6	2M	8
Campos-Rodriguez F., 2019	Spain	31314107	120	IL-6	3M	8
Tirado R., 2017	Spain	28283920	66	IL-1β, IL-6	12M	5
Jin F., 2017	China	28901415	100	IL-8	3M	9
Martínez-Cerón E., 2016	Spain	26910598	26	IL-6, IL-8	6M	8
Kheirandish-Gozal L., 2015	US	25801692	100	IL-6	< 6M	5
Arnardottir E.S., 2015	Iceland	25359691	177	IL-6	24M	8
Akinnusi M., 2013	US	23239459	25	IL-6, IL-8, IL-10	2M	6
Kezirian E.J., 2010	US	20564750	21	IL-6	3M	6
Eun Y.G., 2010	Korea	20632906	51	IL-6	1M	5
Ye L., 2010	China	20668869	10	IL-6	6M	7
Steiropoulos P., 2009	Greece	19413148	32	IL-6	6M	8
Li A.M., 2008	China	–	16	IL-6, IL-8	2–3M	8
Li Y., 2008 (a)*	China	18311073	33	IL-6, IL-10	2M	7
Li Y., 2008 (b)*			5
Li Y., 2008 (c)*			2
Takahashi K.I. 2008	Japan	18199002	27	IL-6	1M	8
Dorkova Z., 2008	Slovakia	18625666	16	IL-6	2M	8
Ryan S., 2006	Ireland	16840748	49	IL-6, IL-8, IL-10	1.5M	5
Bao H.R., 2005	China	-	10	IL-8, IL-10	6M	7

IL, interleukin; No., number of patients with OSA included in analysis. NOS represents Newcastle-Ottawa Scale, which is used for article quality evaluation. The period is measured in months. *: (a), (b), and (c) represent the different population from the same paper.

For the references for the included study, please refer to Supplemental Table 4.